LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (Nasdaq: SGEN) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Seattle Genetics shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The Complaint alleges that Seattle Genetics revealed that the U.S. Food and Drug Administration had issued a clinical stop on initial stage trials of the Company's experimental cancer drug, vadastuximab talirine, to assess any potential outcome of hepatotoxicity. Seattle Genetics disclosed that six acute myeloid leukemia patients had liver toxicity and that four had died.
When this information was disclosed to the public, Seattle Genetics stock fell in value, causing investors serious harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.